AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03740711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial venting
Description: The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
Study NCT02088047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProFoveate
Description: ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
Study NCT00492908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helistent Titan2 (Titanium coated stent)
Description: Titan2
Study NCT00492908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndeavorTM (Zotarolimus-Eluting Stent)
Description: Endeavor
Study NCT04525911 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: serology test for COVID-19
Description: a serology test will be performed at M3
Study NCT03416972 — intervention group
Intervention type: RADIATION
Intervention: Standard platinum-based chemoradiotherapy
Description: Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
Study NCT00516906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
Study NCT00516906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transparent Adhesive Dressing
Description: Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
Study NCT05405348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The patients did not eat anything during hemodialysis.
Study NCT05300828 — intervention group
Intervention type: DRUG
Intervention: Genexl PM
Description: Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.
Study NCT04032236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: caffeine
Description: At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
Study NCT04898569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Ferric carboxymaltose injection
Study NCT04898569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush
Description: placebo
Study NCT00371345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
Study NCT03712514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Destabilization of the upper cervical spine by Cervistab
Description: Simulate a situation of destabilization of the cervical spine with Cervistab
Study NCT04197661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.2 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study NCT04197661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.3 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study NCT04197661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study NCT05479656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: 8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
Study NCT02345837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial sampling
Description: injury to the endometrium
Study NCT02345837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction by 100mg clomiphene citrate
Study NCT01682395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection and anastomosis
Description: Resection of sigmoid colon with primary anastomosis
Study NCT01682395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection and anastomosis
Description: Resection of sigmoid colon with primary anastomosis
Study NCT01682395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection and colostomy
Description: Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
Study NCT01682395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesosigmoidopexy
Description: Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
Study NCT02288156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: via nasal spray
Study NCT02288156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: via nasal spray
Study NCT02288156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: via nasal spray
Study NCT02593253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit and Feedback Bundle
Description: The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
Study NCT02593253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bi-weekly audit and feedback emails
Description: The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
Study NCT01502410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
Study NCT01502410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study NCT00371345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg
Description: Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
Study NCT03234374 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INL-001 (bupivacaine HCl collagen implant)
Description: 3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
Study NCT03319329 — intervention group
Intervention type: DEVICE
Intervention: Indirect Calorimetry
Description: REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein \& Coulter, 2014);(P. Singer \& Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
Study NCT03160872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti Mullerian Hormone Measurement
Description: Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
Study NCT02627196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO® System
Study NCT02627196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management
Study NCT02627196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Study NCT03686462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-based interactive treadmill training
Description: During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
Study NCT03686462 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Treadmill training without VR-based interaction
Description: Treadmill training without VR-based interaction
Study NCT04443205 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: Data record
Study NCT00979264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive quality improvement tools
Description: Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
Study NCT04111185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receive Blood Volume Analysis Guided Treatment
Description: The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
Study NCT01502410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT03016624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided PCI
Description: oct guided
Study NCT03016624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided PCI
Description: angio guided
Study NCT01534299 — intervention group
Intervention type: DEVICE
Intervention: Medtronic Renal Denervation System
Description: The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
Study NCT04115878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine and oxybutynin (ato-oxy)
Description: Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
Study NCT02031991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06439535
Description: Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
Study NCT02031991 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
Study NCT04653090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Xray
Description: Hip AP Xray
Study NCT02782975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aducanumab
Study NCT00616395 — intervention group
Intervention type: DEVICE
Intervention: No intervention
Study NCT01699282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VKA (antivitamin K) education
Description: Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
Study NCT01699282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional hospital education
Description: Group thorough VKA education V.S. control group (conventional hospital education)
Study NCT04186520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
Study NCT04186520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Cryopreserved Car-T Cells
Description: A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
Study NCT04186520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
Study NCT00754260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine reduction
Description: patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
Study NCT01116011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Capsule, Oral, BID
Study NCT01116011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, BID
Study NCT03241251 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Questionnaire of psychosocial risk factors
Study NCT05787457 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Study NCT05787457 — intervention group
Intervention type: OTHER
Intervention: Blood testing
Study NCT05787457 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT00603889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2 Skin Test Reagent
Description: Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
Study NCT03234686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone 600mg delayed release tablets
Description: The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
Study NCT03234686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
Study NCT02235480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Tazarotene Gel
Study NCT02235480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00160251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
Study NCT00160251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
Study NCT03234374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25% infiltration
Description: Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
Study NCT03204032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur 40-60mg po bid(d1-d14);
Study NCT00160251 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously
Study NCT00160251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously
Study NCT03204032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur
Description: Tegafur 40-60mg po bid(d1-d14);
Study NCT03204032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200mg po qd(d10-d14)
Study NCT03204032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 200mg po qd(d10-d14)
Study NCT03204032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
Study NCT00354484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
Study NCT00354484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
Study NCT04161313 — intervention group
Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test.
Study NCT04161313 — intervention group
Intervention type: OTHER
Intervention: pulmonary function test
Description: It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
Study NCT04161313 — intervention group
Intervention type: OTHER
Intervention: Functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
Study NCT04161313 — intervention group
Intervention type: OTHER
Intervention: Peripheral muscle strength
Description: Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
Study NCT04161313 — intervention group
Intervention type: OTHER
Intervention: Respiratory muscle strength
Description: Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
Study NCT04290767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)
Description: Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
Study NCT04396106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-527
Description: One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
Study NCT04396106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
Study NCT04396106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-527
Description: Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
Study NCT04396106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
Study NCT02397772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole
Description: Single dose of albendazole (400 mg)
Study NCT02397772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: Single dose of albendazole (400 mg)
Study NCT01723124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
Study NCT01081951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Tablets Oral BID
Study NCT00998452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE*VETS
Description: Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
Study NCT03021655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventure-based intervention group
Description: One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
Study NCT03021655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp intervention group
Description: A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.